Comparison in Prostate Cancer Diagnosis with PSA 4-10 Ng/mL: Radiomics-based Model VS. PI-RADS V2.1

Overview

Journal BMC Urol

Publisher Biomed Central

Specialty Urology

Date 2024 Oct 24

PMID 39443896

Authors

Chunxing Li

Zhicheng Jin

Chaogang Wei

Guangcheng Dai

Jian Tu

Junkang Shen

Affiliations

Soon will be listed here.

Abstract

Background: To evaluate accuracy of MRI-based radiomics in diagnosing prostate cancer (PCa) in patients with PSA levels between 4 and 10 ng/mL and compare it with the latest Prostate Imaging Reporting and Data System (PI-RADS v2.1) score.

Methods: 221 patients with prostate lesions and PSA levels in 4-10 ng/mL, including 154 and 67 cases in the training and validation groups. Pathological confirmation of all patients was accomplished by the use of MRI-TRUS fusion targeted biopsy or systematic transrectal ultrasound (TRUS) guided biopsy. 851 radiomic features were extracted from each lesion of ADC and T2WI images. The least absolute shrinkage and selection operator (LASSO) regression algorithm and logistic regression were employed to select features and build the ADC and T2WI model. The combined model was obtained based on the ADC and T2WI features. The clinical benefit and diagnostic accuracy of the three radiomics models and PI-RADS v2.1 score were evaluated.

Results: 10 radiomic features were ultimately selected from the ADC images, 13 from the T2WI images and 7 from the combined models. The ADC, T2WI and combined models achieved satisfactory diagnostic accuracy in the training [AUC:0.945 (ADC), 0.939 (T2WI), 0.979 (combined)] and validation groups [AUC: 0.942 (ADC), 0.943 (T2WI), 0.959 (combined)], which was significantly higher than those in PI-RADS v2.1 model (0.825 for training cohort and 0.853 for validation cohort). Compared with the PI-RADS v2.1 score, the three radiomics models generated superior PCa diagnostic performance in both the training (p = 0.002, p = 0.005, p < 0.001) and validation groups (p = 0.045, p = 0.035, p = 0.015).

Conclusion: Radiomics based on ADC and T2WI images can better identify PCa in patients with PSA 4-10 ng/mL, and MRI-based radiomics significantly outperforms the PI-RADS v2.1 score.

Clinical Trial Number: Not applicable.

References

Yadav S, Stockert J, Hackert V, Yadav K, Tewari A . Intratumor heterogeneity in prostate cancer. Urol Oncol. 2018; 36(8):349-360. DOI: 10.1016/j.urolonc.2018.05.008. View

Byun J, Park K, Kim M, Kim J . Direct Comparison of PI-RADS Version 2 and 2.1 in Transition Zone Lesions for Detection of Prostate Cancer: Preliminary Experience. J Magn Reson Imaging. 2020; 52(2):577-586. DOI: 10.1002/jmri.27080. View

Koo T, Li M . A Guideline of Selecting and Reporting Intraclass Correlation Coefficients for Reliability Research. J Chiropr Med. 2016; 15(2):155-63. PMC: 4913118. DOI: 10.1016/j.jcm.2016.02.012. View

Qi Y, Zhang S, Wei J, Zhang G, Lei J, Yan W . Multiparametric MRI-Based Radiomics for Prostate Cancer Screening With PSA in 4-10 ng/mL to Reduce Unnecessary Biopsies. J Magn Reson Imaging. 2019; 51(6):1890-1899. DOI: 10.1002/jmri.27008. View

Dwivedi D, Kumar R, Dwivedi A, Bora G, Thulkar S, Sharma S . Prebiopsy multiparametric MRI-based risk score for predicting prostate cancer in biopsy-naive men with prostate-specific antigen between 4-10 ng/mL. J Magn Reson Imaging. 2017; 47(5):1227-1236. DOI: 10.1002/jmri.25850. View

Siegel R, Miller K, Wagle N, Jemal A . Cancer statistics, 2023. CA Cancer J Clin. 2023; 73(1):17-48. DOI: 10.3322/caac.21763. View

Zhang L, Zhang J, Tang M, Lei X, Li L . MRI-Based Radiomics Nomogram for Predicting Prostate Cancer with Gray-Zone Prostate-Specific Antigen Levels to Reduce Unnecessary Biopsies. Diagnostics (Basel). 2022; 12(12). PMC: 9776817. DOI: 10.3390/diagnostics12123005. View

Ginsburg S, Algohary A, Pahwa S, Gulani V, Ponsky L, Aronen H . Radiomic features for prostate cancer detection on MRI differ between the transition and peripheral zones: Preliminary findings from a multi-institutional study. J Magn Reson Imaging. 2016; 46(1):184-193. PMC: 5464994. DOI: 10.1002/jmri.25562. View

Gillies R, Kinahan P, Hricak H . Radiomics: Images Are More than Pictures, They Are Data. Radiology. 2015; 278(2):563-77. PMC: 4734157. DOI: 10.1148/radiol.2015151169. View

10.

Li T, Sun L, Li Q, Luo X, Luo M, Xie H . Development and Validation of a Radiomics Nomogram for Predicting Clinically Significant Prostate Cancer in PI-RADS 3 Lesions. Front Oncol. 2022; 11:825429. PMC: 8825569. DOI: 10.3389/fonc.2021.825429. View

11.

Kumar V, Gu Y, Basu S, Berglund A, Eschrich S, Schabath M . Radiomics: the process and the challenges. Magn Reson Imaging. 2012; 30(9):1234-48. PMC: 3563280. DOI: 10.1016/j.mri.2012.06.010. View

12.

Tamada T, Sone T, Higashi H, Jo Y, Yamamoto A, Kanki A . Prostate cancer detection in patients with total serum prostate-specific antigen levels of 4-10 ng/mL: diagnostic efficacy of diffusion-weighted imaging, dynamic contrast-enhanced MRI, and T2-weighted imaging. AJR Am J Roentgenol. 2011; 197(3):664-70. DOI: 10.2214/AJR.10.5923. View

13.

Chen T, Li M, Gu Y, Zhang Y, Yang S, Wei C . Prostate Cancer Differentiation and Aggressiveness: Assessment With a Radiomic-Based Model vs. PI-RADS v2. J Magn Reson Imaging. 2018; 49(3):875-884. PMC: 6620601. DOI: 10.1002/jmri.26243. View

14.

Turkbey B, Rosenkrantz A, Haider M, Padhani A, Villeirs G, Macura K . Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. Eur Urol. 2019; 76(3):340-351. DOI: 10.1016/j.eururo.2019.02.033. View

15.

Pienta K . Critical appraisal of prostate-specific antigen in prostate cancer screening: 20 years later. Urology. 2009; 73(5 Suppl):S11-20. DOI: 10.1016/j.urology.2009.02.016. View

16.

Zhou Y, Li Y, Li X, Jiang M . Urinary Biomarker Panel to Improve Accuracy in Predicting Prostate Biopsy Result in Chinese Men with PSA 4-10 ng/mL. Biomed Res Int. 2017; 2017:2512536. PMC: 5331314. DOI: 10.1155/2017/2512536. View

17.

Wang J, Wu C, Bao M, Zhang J, Wang X, Zhang Y . Machine learning-based analysis of MR radiomics can help to improve the diagnostic performance of PI-RADS v2 in clinically relevant prostate cancer. Eur Radiol. 2017; 27(10):4082-4090. DOI: 10.1007/s00330-017-4800-5. View

18.

Kuru T, Futterer J, Schiffmann J, Porres D, Salomon G, Rastinehad A . Transrectal Ultrasound (US), Contrast-enhanced US, Real-time Elastography, HistoScanning, Magnetic Resonance Imaging (MRI), and MRI-US Fusion Biopsy in the Diagnosis of Prostate Cancer. Eur Urol Focus. 2017; 1(2):117-126. DOI: 10.1016/j.euf.2015.06.003. View

19.

Han C, Liu S, Qin X, Ma S, Zhu L, Wang X . MRI combined with PSA density in detecting clinically significant prostate cancer in patients with PSA serum levels of 4∼10ng/mL: Biparametric versus multiparametric MRI. Diagn Interv Imaging. 2020; 101(4):235-244. DOI: 10.1016/j.diii.2020.01.014. View

20.

Lu Y, Li B, Huang H, Leng Q, Wang Q, Zhong R . Biparametric MRI-based radiomics classifiers for the detection of prostate cancer in patients with PSA serum levels of 4∼10 ng/mL. Front Oncol. 2022; 12:1020317. PMC: 9793773. DOI: 10.3389/fonc.2022.1020317. View